CarthroniX Completes Convertible Note Financing

Proceeds Will Support Pre-clinical Development and Clinical Advancement of its Lead Candidate, CX-011, for the Treatment of Mild to Moderate Knee Osteoarthritis LOS ANGELES, April 11, 2022 /PRNewswire/ -- CarthroniX, Inc., a California-based startup developing novel small molecule...

Click to view original post